Theravance Biopharma (TBPH) Trading -3.4% Higher Following Analyst Upgrade
Theravance Biopharma Inc (NASDAQ:TBPH) traded up 3.4% during trading on Thursday after Leerink Swann raised their price target on the stock from $45.00 to $48.00. Leerink Swann currently has an outperform rating on the stock. Theravance Biopharma traded as high as $29.62 and last traded at $27.06. 144,692 shares were traded during mid-day trading, a decline of 38% from the average session volume of 234,206 shares. The stock had previously closed at $28.01.
TBPH has been the subject of a number of other reports. ValuEngine lowered Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. Cantor Fitzgerald reissued a “buy” rating and issued a $55.00 price target on shares of Theravance Biopharma in a research report on Tuesday, November 7th. Needham & Company LLC reissued a “buy” rating on shares of Theravance Biopharma in a research report on Tuesday, December 5th. BidaskClub lowered Theravance Biopharma from a “sell” rating to a “strong sell” rating in a research report on Saturday, February 3rd. Finally, Robert W. Baird reissued a “sell” rating and issued a $22.00 price target on shares of Theravance Biopharma in a research report on Wednesday, November 1st. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $42.00.
Large investors have recently made changes to their positions in the business. BlackRock Inc. grew its stake in Theravance Biopharma by 3.6% in the 2nd quarter. BlackRock Inc. now owns 3,638,838 shares of the biopharmaceutical company’s stock valued at $144,972,000 after purchasing an additional 126,393 shares during the period. Alps Advisors Inc. grew its stake in Theravance Biopharma by 10.3% in the 3rd quarter. Alps Advisors Inc. now owns 53,013 shares of the biopharmaceutical company’s stock valued at $1,815,000 after purchasing an additional 4,944 shares during the period. New York State Common Retirement Fund grew its stake in Theravance Biopharma by 9.2% in the 2nd quarter. New York State Common Retirement Fund now owns 46,300 shares of the biopharmaceutical company’s stock valued at $1,845,000 after purchasing an additional 3,899 shares during the period. Northern Trust Corp grew its stake in Theravance Biopharma by 6.1% in the 2nd quarter. Northern Trust Corp now owns 530,049 shares of the biopharmaceutical company’s stock valued at $21,117,000 after purchasing an additional 30,611 shares during the period. Finally, Vanguard Group Inc. grew its stake in Theravance Biopharma by 3.8% in the 2nd quarter. Vanguard Group Inc. now owns 3,197,277 shares of the biopharmaceutical company’s stock valued at $127,379,000 after purchasing an additional 116,981 shares during the period. Hedge funds and other institutional investors own 86.04% of the company’s stock.
Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.05). Theravance Biopharma had a negative net margin of 1,604.87% and a negative return on equity of 99.43%. sell-side analysts predict that Theravance Biopharma Inc will post -4.84 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This piece was reported by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2018/02/08/theravance-biopharma-tbph-trading-3-4-higher-following-analyst-upgrade.html.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.